Table of Contents
(Source: Value in Health)
Source: Value in Health - October 28, 2020 Category: International Medicine & Public Health Source Type: research

Copyright/Subscription
(Source: Value in Health)
Source: Value in Health - October 28, 2020 Category: International Medicine & Public Health Source Type: research

Editorial Board
(Source: Value in Health)
Source: Value in Health - October 28, 2020 Category: International Medicine & Public Health Source Type: research

Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening
This article illustrates the value of metamodeling for evaluating colorectal cancer screening strategies while accounting for colonoscopy capacity constraints. (Source: Value in Health)
Source: Value in Health - October 27, 2020 Category: International Medicine & Public Health Authors: Hendrik Koffijberg, Koen Degeling, Maarten J. IJzerman, Veerle M.H. Coup é, Marjolein J.E. Greuter Source Type: research

Preferences for Accessing Electronic Health Records for Research Purposes: Views of Parents Who Have a Child With a Known or Suspected Genetic Condition
The purpose of this study was to examine parental preferences for researchers accessing their child ’s electronic health record across 3 groups: those with a child with (1) a known genetic condition (fragile X syndrome FXS), (2) a suspected genetic condition (autism spectrum disorder [ASD]), and (3) no known genetic condition (typically developing). (Source: Value in Health)
Source: Value in Health - October 26, 2020 Category: International Medicine & Public Health Authors: Melissa Raspa, Ryan S. Paquin, Derek S. Brown, Sara Andrews, Anne Edwards, Rebecca Moultrie, Laura Wagner, MaryKate Frisch, Lauren Turner-Brown, Anne C. Wheeler Source Type: research

Economic Evaluation in Opioid Modeling: Systematic Review
The rapid increase in opioid overdose and opioid use disorder (OUD) over the past 20 years is a complex problem associated with significant economic costs for healthcare systems and society. Simulation models have been developed to capture and identify ways to manage this complexity and to evaluate the potential costs of different strategies to reduce overdoses and OUD. A review of simulation-based economic evaluations is warranted to fully characterize this set of literature. (Source: Value in Health)
Source: Value in Health - October 26, 2020 Category: International Medicine & Public Health Authors: Elizabeth Beaulieu, Catherine DiGennaro, Erin Stringfellow, Ava Connolly, Ava Hamilton, Ayaz Hyder, Magdalena Cerd á, Katherine M. Keyes, Mohammad S. Jalali Source Type: research

Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products
To estimate the effect of filgrastim-sndz market entry on patient out-of-pocket costs and claim payments for filgrastim products. (Source: Value in Health)
Source: Value in Health - October 23, 2020 Category: International Medicine & Public Health Authors: Morgane C. Mouslim, Antonio J. Trujillo, G. Caleb Alexander, Jodi B. Segal Source Type: research

A Systematic Review and Meta-Analysis of Change in Health-Related Quality of Life for Interactive Telehealth Interventions for Patients With Asthma
This study examines and synthesizes the available data on the change in the QOL for patients with asthma who use interactive telehealth interventions, and identifies the most effective telehealth modalities used for intervention in this area. (Source: Value in Health)
Source: Value in Health - October 23, 2020 Category: International Medicine & Public Health Authors: Centaine L. Snoswell, Miia Rahja, Aislinn F. Lalor Source Type: research

Commentary on “Cost-Effectiveness of the Wellness Incentives and Navigation Program”
Economic evaluations of programs for people with comorbid physical and mental illness with a focus on patient self-efficacy are uncommon, especially in the context of a randomized control trial;1 so the economic evaluation of the Wellness Incentive and Navigation (WIN) program2 is welcome. (Source: Value in Health)
Source: Value in Health - October 22, 2020 Category: International Medicine & Public Health Authors: Leonie Segal Source Type: research

Factors Affecting Buprenorphine Utilization and Spending in Medicaid, 2002-2018
Buprenorphine is an essential medication for the treatment of opioid use disorder (OUD), but studies show it has been underused over the last 2 decades. We sought to evaluate utilization of and spending on buprenorphine formulations in Medicaid and to evaluate the impact of key market and regulatory factors affecting availability of different formulations and generic versions. (Source: Value in Health)
Source: Value in Health - October 21, 2020 Category: International Medicine & Public Health Authors: Rachel E. Barenie, Michael S. Sinha, Aaron S. Kesselheim Source Type: research

Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?
Partitioned survival models (PSMs) are routinely used to inform reimbursement decisions for oncology drugs. We discuss the appropriateness of PSMs compared to the most common alternative, state transition models (STMs). (Source: Value in Health)
Source: Value in Health - October 17, 2020 Category: International Medicine & Public Health Authors: Beth S. Woods, Eleftherios Sideris, Stephen Palmer, Nick Latimer, Marta Soares Source Type: research

Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches
Vaccination has prevented millions of deaths and cases of disease in low- and middle-income countries (LMICs). During the Decade of Vaccines (2011-2020), international organizations, including the World Health Organization and Gavi, the Vaccine Alliance, focused on new vaccine introduction and expanded coverage of existing vaccines. As Gavi, other organizations, and country governments look to the future, we aimed to estimate the economic benefits of immunization programs made from 2011 to 2020 and potential gains in the future decade. (Source: Value in Health)
Source: Value in Health - October 17, 2020 Category: International Medicine & Public Health Authors: Elizabeth Watts, So Yoon Sim, Dagna Constenla, Salin Sriudomporn, Logan Brenzel, Bryan Patenaude Source Type: research

Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation
The quality-adjusted life-year (QALY) has been long debated, but alternative estimation approaches have not been comprehensively evaluated. Our objective was to identify alternatives, characterize them by implementation feasibility, and evaluate the impact of implementing feasible options in cost-effectiveness models developed for the Institute for Clinical and Economic Review reports. (Source: Value in Health)
Source: Value in Health - October 16, 2020 Category: International Medicine & Public Health Authors: Josh J. Carlson, Elizabeth D. Brouwer, Eunice Kim, Phoebe Wright, R. Brett McQueen Source Type: research

Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018
This study aimed to investigate whether country-level decisions about HPV vaccine introduction are consistent with a particular cost-effectiveness threshold, and to estimate what that threshold may be. (Source: Value in Health)
Source: Value in Health - October 16, 2020 Category: International Medicine & Public Health Authors: Mark Jit Source Type: research

The Role of Health Economics and Outcomes Research in Addressing Coronavirus Disease 2019 (COVID-19)
While the world awaits new treatments and vaccines for coronavirus disease 2019 (COVID-19), the health economics and outcomes research (HEOR) community is already examining various aspects of the novel coronavirus severe acute respiratory syndrome coronavirus 2  of the genus Betacoronavirus (SARS-CoV-2) pandemic. At this point, the emerging literature mainly considers the cost of the pandemic and health economic issues surrounding the development of policies. Some modeling work is being conducted to determine the potential value of future treatments or v accines, and those models will no doubt be tailored and use...
Source: Value in Health - October 13, 2020 Category: International Medicine & Public Health Authors: C. Daniel Mullins, Michael F. Drummond Source Type: research

Machine Learning Improves the Identification of Individuals With Higher Morbidity and Avoidable Health Costs After Acute Coronary Syndromes
Traditional risk scores improved the definition of the initial therapeutic strategy in acute coronary syndrome (ACS), but they were not designed for predicting long-term individual risks and costs. In parallel, attempts to directly predict costs from clinical variables in ACS had limited success. Thus, novel approaches to predict cardiovascular risk and health expenditure are urgently needed. Our objectives were to predict the risk of major/minor adverse cardiovascular events (MACE) and estimate assistance-related costs. (Source: Value in Health)
Source: Value in Health - October 12, 2020 Category: International Medicine & Public Health Authors: Luiz S érgio Fernandes de Carvalho, Silvio Gioppato, Marta Duran Fernandez, Bernardo Carvalho Trindade, José Carlos Quinaglia e Silva, Rebeca Gouget Sérgio Miranda, José Roberto Matos de Souza, Wilson Nadruz, Sandra Eliza Fontes Avila, Andrei Carvalho Source Type: research

Evaluating Vaccination Programs That Prevent Diseases with Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction?
In the last 5 years, guidelines have been developed for performing cost-effectiveness analyses (CEAs) for the economic evaluation of vaccination programs against infectious diseases. However, these cost-effectiveness guidelines do not provide specific guidance for including the value of reducing the risk of rare but potentially catastrophic health outcomes, such as mortality or long-term sequelae. Alternative economic evaluation methods, including extended CEA, the impact inventory, cost-benefit analyses, willingness to pay or the value of a statistical life, to capture the value of this risk reduction could provide more c...
Source: Value in Health - October 12, 2020 Category: International Medicine & Public Health Authors: Josephine Mauskopf, Catherine Masaquel, Liping Huang Source Type: research

Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis
To measure access to opioid treatment programs (OTPs) and office-based buprenorphine treatment (OBBTs) at the smallest geographic unit for which the Census Bureau publishes demographic and socioeconomic data (ie, block group) and to explore disparities in access to treatment across the rural-urban and area deprivation continua across the United States. (Source: Value in Health)
Source: Value in Health - October 10, 2020 Category: International Medicine & Public Health Authors: Solmaz Amiri, Michael G. McDonell, Justin T. Denney, Dedra Buchwald, Ofer Amram Source Type: research

A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole
Reexamine cost-effectiveness of riluzole in the treatment of amyotrophic lateral sclerosis (ALS) in light of recent advances in disease staging and understanding of stage-specific drug effect. (Source: Value in Health)
Source: Value in Health - October 9, 2020 Category: International Medicine & Public Health Authors: Nimish J. Thakore, Erik P. Pioro, Belinda L. Udeh, Brittany R. Lapin, Irene L. Katzan Source Type: research

Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income
This article aims to estimate the cost-effectiveness of scaling up these interventions by scenarios, regions, and income groups. (Source: Value in Health)
Source: Value in Health - October 9, 2020 Category: International Medicine & Public Health Authors: David Tordrup, Yvan Hutin, Karin Stenberg, Jeremy A. Lauer, David W. Hutton, Mehlika Toy, Nick Scott, Jagpreet Chhatwal, Andrew Ball Source Type: research

Estimating Cost Functions for Resource Allocation Using Transmission Models: A Case Study of Tuberculosis Case Finding in South Africa
We present a conceptual and empirical approach for estimating these functions, allowing for nonconstant marginal costs. We aim to expand on the current approach which commonly assumes linearity of cost over scale. (Source: Value in Health)
Source: Value in Health - October 9, 2020 Category: International Medicine & Public Health Authors: Gabriela B. Gomez, Don L. Mudzengi, Fiammetta Bozzani, Nicholas A. Menzies, Anna Vassall Source Type: research

Economic Evaluations in National Cancer Institute –Sponsored Network Cancer Clinical Trials
Amid a rapid increase in cancer care costs, we examined the extent to which economic evaluations (EEs) were conducted for new treatments evaluated in clinical trials at SWOG, a large National Cancer Institute –sponsored cancer research network. (Source: Value in Health)
Source: Value in Health - October 8, 2020 Category: International Medicine & Public Health Authors: Van T. Nghiem, Riha Vaidya, Gary H. Lyman, Dawn L. Hershman, Scott D. Ramsey, Joseph M. Unger Source Type: research

Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group
Value Health. 2020;23(5):529-539. (Source: Value in Health)
Source: Value in Health - October 5, 2020 Category: International Medicine & Public Health Tags: Correction Source Type: research

The Nature and Predictors of Response Changes in Modified-Delphi Panels
To describe the extent and nature of changes in participants ’ responses after exposure to group feedback and discussion in modified-Delphi panels and to identify factors affecting those changes. (Source: Value in Health)
Source: Value in Health - October 4, 2020 Category: International Medicine & Public Health Authors: Dmitry Khodyakov, Christine Chen Source Type: research

Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group
It is expected that the coronavirus disease 2019 (COVID-19) pandemic will leave large deficits in the budgets of many jurisdictions. Funding for other treatments, in particular new treatments, may become more constrained than previously expected. Therefore, a robust health technology assessment (HTA) system is vital. Many clinical trials carried out during the pandemic may have been temporarily halted, while others may have had to change their protocols. Even trials that continue as normal may experience external changes as other aspects of the healthcare service may not be available to the patients in the trial, or the pa...
Source: Value in Health - October 4, 2020 Category: International Medicine & Public Health Authors: Joy Leahy, Conor Hickey, David McConnell, Owen Cassidy, Lea Trela-Larsen, Michael Barry, Lesley Tilson, Laura McCullagh, NCPE Review Group Source Type: research

Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis
The ambitious goals of the US Ending the HIV Epidemic initiative will require a targeted, context-specific public health response. Model-based economic evaluation provides useful guidance for decision making while characterizing decision uncertainty. We aim to quantify the value of eliminating uncertainty about different parameters in selecting combination implementation strategies to reduce the public health burden of HIV/AIDS in 6 US cities and identify future data collection priorities. (Source: Value in Health)
Source: Value in Health - October 2, 2020 Category: International Medicine & Public Health Authors: Xiao Zang, Hawre Jalal, Emanuel Krebs, Ankur Pandya, Haoxuan Zhou, Benjamin Enns, Bohdan Nosyk Source Type: research

Practical Guidance for Including Future Costs in Economic Evaluations in the Netherlands: Introducing and Applying PAID 3.0
A consensus has been reached in The Netherlands that all future medical costs should be included in economic evaluations. Furthermore, internationally, there is the recognition that in countries that adopt a societal perspective estimates of future nonmedical consumption are relevant for decision makers as much as production gains are. The aims of this paper are twofold: (1) to update the tool Practical Application to Include Future Disease Costs (PAID 1.1), based on 2013 data, for the estimation of future unrelated medical costs and introduce future nonmedical consumption costs, further standardizing and facilitating the ...
Source: Value in Health - October 1, 2020 Category: International Medicine & Public Health Authors: Klas Kellerborg, Meg Perry-Duxbury, Linda de Vries, Pieter van Baal Source Type: research

Table of Contents
(Source: Value in Health)
Source: Value in Health - September 30, 2020 Category: International Medicine & Public Health Source Type: research

Copyright/Subscription
(Source: Value in Health)
Source: Value in Health - September 30, 2020 Category: International Medicine & Public Health Source Type: research

Editorial Board
(Source: Value in Health)
Source: Value in Health - September 30, 2020 Category: International Medicine & Public Health Source Type: research

Cost-Effectiveness of Immediate Magnetic Resonance Imaging in the Management of Patients With Suspected Scaphoid Fracture: Results From a Randomized Clinical Trial
Given the limited diagnostic accuracy of radiographs on presentation to the emergency department (ED), the management of suspected scaphoid fractures remains clinically challenging and poses an unknown economic burden to healthcare systems. We aimed to evaluate the cost-effectiveness of immediate magnetic resonance imaging (MRI) in the management of patients presenting with suspected scaphoid fracture to an ED in England. (Source: Value in Health)
Source: Value in Health - September 28, 2020 Category: International Medicine & Public Health Authors: Tiago Rua, Sam Gidwani, Bharti Malhotra, Sanjay Vijayanathan, Laura Hunter, Janet Peacock, Joanna Turville, Reza Razavi, Vicky Goh, Paul McCrone, James Shearer Source Type: research

Modifying the Criteria for Granting Orphan Drug Market Exclusivity
To examine policy options to deny orphan drug exclusivity after drugs exceed a target population of 200  000 across all orphan indications (combined prevalence threshold) or once drugs receive a nonorphan approval (market approval threshold). (Source: Value in Health)
Source: Value in Health - September 27, 2020 Category: International Medicine & Public Health Authors: Mariana P. Socal, Sonal Parasrampuria, Gerard F. Anderson Source Type: research

The Cost-Effectiveness of Different Formats for Delivery of Cognitive Behavioral Therapy for Depression: A Systematic Review Based Economic Model
Cognitive behavioral therapy (CBT) is an effective treatment for depression. Different CBT delivery formats (face-to-face [F2F], multimedia, and hybrid) and intensities have been used to expand access to the treatment. The aim of this study is to estimate the long-term cost-effectiveness of different CBT delivery modes. (Source: Value in Health)
Source: Value in Health - September 22, 2020 Category: International Medicine & Public Health Authors: Qi Wu, Jinshuo Li, Steve Parrott, Jos é Antonio López-López, Sarah R. Davies, Deborah M. Caldwell, Rachel C. Churchill, Tim J. Peters, Glyn Lewis, Debbie Tallon, Sarah Dawson, Abigail Taylor, David S. Kessler, Nicola Wiles, Nicky J. Welton Source Type: research

Informing Balanced Investment in Services and Health Systems: A Case Study of Priority Setting for Tuberculosis Interventions in South Africa
Health systems face nonfinancial constraints that can influence the opportunity cost of interventions. Empirical methods to explore their impact, however, are underdeveloped. We develop a conceptual framework for defining health system constraints and empirical estimation methods that rely on routine data. We then present an empirical approach for incorporating nonfinancial constraints in cost-effectiveness models of health benefit packages for the health sector. (Source: Value in Health)
Source: Value in Health - September 18, 2020 Category: International Medicine & Public Health Authors: Fiammetta M. Bozzani, Tom Sumner, Don Mudzengi, Gabriela B. Gomez, Richard White, Anna Vassall Source Type: research

Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial
Evaluate the effects of intravenous golimumab 2 mg/kg on multiple domains of health-related quality of life (HRQoL) in adult patients with active psoriatic arthritis (PsA). (Source: Value in Health)
Source: Value in Health - September 17, 2020 Category: International Medicine & Public Health Authors: M. Elaine Husni, Arthur Kavanaugh, Eric K.H. Chan, Steven Peterson, Nan Li, Elizabeth C. Hsia, Lilianne Kim, Kim Hung Lo, Diane D. Harrison, Chenglong Han Source Type: research

Head-to-head comparison of the psychometric properties of 3 carer-related preference-based instruments
To compare the psychometric properties of the Adult Social Care Outcomes Toolkit for carers (ASCOT-Carer), the Carer Experience Scale (CES), and the Care-related Quality of Life (CarerQol) to inform the choice of instrument in future studies. (Source: Value in Health)
Source: Value in Health - September 17, 2020 Category: International Medicine & Public Health Authors: Nikki McCaffrey, Jessica Bucholc, Stacey Rand, Renske Hoefman, Anna Ugalde, Anne Muldowney, Cathrine Mihalopoulos, Lidia Engel Source Type: research

Donor Kidney Quality and Transplant Outcome: An Economic Evaluation of Contemporary Practice
The study had two main aims. First, we assessed the cost-effectiveness of transplanting deceased donor kidneys of differing quality levels based on the Kidney Donor Profile Index (KDPI). Second, we assessed the cost-effectiveness of remaining on the waiting list until a high-quality kidney becomes available compared to transplanting a lower-quality kidney. (Source: Value in Health)
Source: Value in Health - September 14, 2020 Category: International Medicine & Public Health Authors: Sameera Senanayake, Nicholas Graves, Helen Healy, Keshwar Baboolal, Adrian Barnett, Matthew P. Sypek, Sanjeewa Kularatna Source Type: research

Use of Real-World Evidence to Support FDA Approval of Oncology Drugs
Real-world evidence (RWE) has gained increased attention in recent years as a complement to traditional clinical trials. The use of RWE to establish the efficacy of oncology drugs for Food and Drug Administration (FDA) approval has not been described. In this paper, we review 5 recent examples where RWE was submitted in support of the FDA approvals of original or supplementary indications for oncology drugs. (Source: Value in Health)
Source: Value in Health - September 13, 2020 Category: International Medicine & Public Health Authors: Bruce A. Feinberg, Ajeet Gajra, Marjorie E. Zettler, Todd D. Phillips, Eli G. Phillips, Jonathan K. Kish Source Type: research

Testing the “Nonstopping” Time Trade-Off: Is It Better Than the Composite Time Trade-Off?
In this study, we aimed to test the feasibility of n-TTO and compared it with c-TTO. (Source: Value in Health)
Source: Value in Health - September 13, 2020 Category: International Medicine & Public Health Authors: Nan Luo, Liv Augestad, Kim Rand Source Type: research

Patient –Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care
This study examined the association of patient–provider cost discussion with out-of-pocket spending among cancer survivors. (Source: Value in Health)
Source: Value in Health - September 11, 2020 Category: International Medicine & Public Health Authors: Young-Rock Hong, Ramzi G. Salloum, Sandhya Yadav, Grace Smith, Arch G. Mainous Source Type: research

Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients
This study aims to investigate the cost-effectiveness of monitoring abiraterone Cmin in patients with mCRPC. (Source: Value in Health)
Source: Value in Health - September 10, 2020 Category: International Medicine & Public Health Authors: Renske M.T. ten Ham, Merel van Nuland, Rick A. Vreman, Laurens G. de Graaf, Hilde Rosing, Andr é M. Bergman, Alwin D.R. Huitema, Jos H. Beijnen, Anke M. Hövels Source Type: research

Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review
In this study, we aimed to identify and assess the methodological quality of studies that used claims data to compare the effectiveness, costs, or cost-effectiveness of systemic therapies for breast cancer. (Source: Value in Health)
Source: Value in Health - September 9, 2020 Category: International Medicine & Public Health Authors: Marianne Luyendijk, Robin W.M. Vernooij, Hedwig M. Blommestein, Sabine Siesling, Carin A. Uyl-de Groot Source Type: research

Optimization Models for HIV/AIDS Resource Allocation: A Systematic Review
This study reviews optimization models for human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) resource allocation. (Source: Value in Health)
Source: Value in Health - September 9, 2020 Category: International Medicine & Public Health Authors: Anton L.V. Avance ña, David W. Hutton Source Type: research

Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial
Evaluate the effect of intravenous golimumab on health-related quality of life (HRQoL) in patients with ankylosing spondylitis (AS) through week 28 of the Phase 3, multicenter, randomized, double-blind, placebo-controlled GO-ALIVE study. (Source: Value in Health)
Source: Value in Health - September 6, 2020 Category: International Medicine & Public Health Authors: John D. Reveille, Atul Deodhar, Akgun Ince, Eric K.H. Chan, Steven Peterson, Nan Li, Elizabeth C. Hsia, Lilianne Kim, Kim Hung Lo, Stephen Xu, Diane D. Harrison, Chenglong Han Source Type: research

How Good Is Machine Learning in Predicting All-Cause 30-Day Hospital Readmission? Evidence From Administrative Data
Hospital readmission is a main cost driver for healthcare systems, but existing works often had poor or moderate predictive results. Although the available information differs in different studies, improving prediction is different from the search for important explanatory variables. With large sample size and abundant information, this study explores state-of-the-art machine-learning algorithms and shows their performance in prediction. (Source: Value in Health)
Source: Value in Health - September 6, 2020 Category: International Medicine & Public Health Authors: Qing Li, Xueqin Yao, Damien Échevin Source Type: research

Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations
To review published economic evaluations of antiviral treatment for pandemics and outbreaks of respiratory illnesses. (Source: Value in Health)
Source: Value in Health - September 4, 2020 Category: International Medicine & Public Health Authors: Dalia M Dawoud, Khaled Y Soliman Source Type: research

Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study
To conduct a discrete-choice experiment to quantify Americans ’ acceptance of severe acute respiratory syndrome coronavirus 2 infection risks for earlier lifting of social-distancing restrictions and diminishing the pandemic’s economic impact. (Source: Value in Health)
Source: Value in Health - September 4, 2020 Category: International Medicine & Public Health Authors: Shelby Reed, Juan Marcos Gonzalez, F. Reed Johnson Source Type: research

Cost-Utility Analysis of a Complex Intervention to Reduce School-Based Bullying and Aggression: An Analysis of the Inclusive RCT
In this study, we evaluated the cost-effectiveness of a complex school-based intervention to address these outcomes within a large-cluster randomized trial (Inclusive). (Source: Value in Health)
Source: Value in Health - September 4, 2020 Category: International Medicine & Public Health Authors: Rosa Legood, Charles Opondo, Emily Warren, Farah Jamal, Chris Bonell, Russell Viner, Zia Sadique Source Type: research

Willingness to Pay for Health Improvements Using Stated Preferences: Prevention Versus Treatment
This study aimed to investigate whether there was a difference in willingness to pay (WTP) between prevention and treatment for health benefits of equal magnitude. (Source: Value in Health)
Source: Value in Health - September 2, 2020 Category: International Medicine & Public Health Authors: Ellen Wolff, Sofie Larsson, Mikael Svensson Source Type: research

Do Discrete Choice Experiments Approaches Perform Better Than Time Trade-Off in Eliciting Health State Utilities? Evidence From SF-6Dv2 in China
To explore the acceptability, consistency, and accuracy of eliciting health state utility values using discrete choice experiment (DCE) and DCE with life duration dimension (DCETTO) as compared with conventional time trade-off (TTO) by using the SF-6Dv2. (Source: Value in Health)
Source: Value in Health - September 2, 2020 Category: International Medicine & Public Health Authors: Shitong Xie, Jing Wu, Xiaoning He, Gang Chen, John E. Brazier Source Type: research